Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Carbamazepine

Drug and asset intelligence for Carbamazepine with 8 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
5
Catalysts
3
Stage
Development stage unavailable

Sponsor company

Zydus Pharmaceuticals →

Recent signals(5)

RegulatoryJuly 31, 2026

FDA Approval Status Update for Carbamazepine ANDA205571 by Zydus Pharmaceuticals

The FDA has granted an approval status of 'AP' for ANDA205571, a supplemental application for Carbamazepine by Zydus Pharmaceuticals.

RegulatoryJuly 28, 2026

FDA Grants AP Status for Carbamazepine ANDA219072 by Yichang Humanwell

The FDA has granted approval status (AP) for the ANDA219072 application for Carbamazepine submitted by Yichang Humanwell.

StrategyJuly 11, 2026

FDA Grants AP Status for Zydus' Carbamazepine ANDA205571

The FDA has granted approval status (AP) for Zydus Pharmaceuticals' ANDA205571 for Carbamazepine.

RegulatoryJuly 8, 2026

FDA Grants AP Status for Carbamazepine ANDA215591 by Zhejiang Jiuzhou

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Carbamazepine submitted by Zhejiang Jiuzhou.

RegulatoryJuly 4, 2026

FDA Grants AP Status for Carbamazepine ANDA219072 by Yichang Humanwell

The FDA has granted approval status (AP) for the ANDA219072 application for Carbamazepine submitted by Yichang Humanwell.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(3)

Topline Data

Zydus Pharmaceuticals — Carbamazepine

July 11, 2026 · N/A

Topline Data

— Carbamazepine

July 8, 2026 · N/A

Topline Data

— Carbamazepine

July 4, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Antiepileptic →
Neurology →
Neurology · Antiepileptic →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.